Nonalcoholic steatohepatitis (NASH) affects 2%-3% of the US population and is expected to become the leading indication for liver transplantation in the next decade. Bariatric surgery may be an effective but expensive treatment for NASH. Using a state-transition model, our analysis assessed the effectiveness and cost-effectiveness of surgery to manage NASH. We simulated the benefits and harms of laparoscopic Roux-en-Y gastric bypass surgery in patients defined by weight class (overweight, mild obesity, moderate obesity, and severe obesity) and fibrosis stage (F0-F3). Comparators included intensive lifestyle intervention (ILI) and no treatment. Quality-adjusted life years (QALYs), costs, and incremental costeffectiveness ratios were calculated. Our results showed that surgery and ILI in obese patients (with F0-F3) increased QALYs by 0.678-2.152 and 0.452-0.618, respectively, compared with no treatment. Incremental cost-effectiveness ratios for surgery in all F0-F3 patients with mild, moderate, or severe obesity were $48,836/QALY, $24,949/QALY, and $19,222/QALY, respectively. In overweight patients (with F0-F3), surgery increased QALYs by 0.050-0.824 and ILI increased QALYs by 0.031-0.164. In overweight patients, it was cost-effective to reserve treatment only for F3 patients; the incremental cost-effectiveness ratios for providing surgery or ILI only to F3 patients were $30,484/QALY and $25,367/QALY, respectively. Conclusions: Surgery was both effective and cost-effective for obese patients with NASH, regardless of fibrosis stage; in overweight patients, surgery increased QALYs for all patients regardless of fibrosis stage, but was cost-effective only for patients with F3 fibrosis; our results highlight the promise of bariatric surgery for treating NASH and underscore the need for clinical trials in this area. (HEPATOLOGY 2017;65:1156-1164.
I
n the United States, the prevalence of obesity is expected to reach 40% by 2025. (1) Obesity is strongly associated with nonalcoholic fatty liver disease, the most common liver disease in the western world. In the United States, 2%-3% of the population has nonalcoholic steatohepatitis (NASH), the progressive form of nonalcoholic fatty liver disease, which can give rise to cirrhosis and hepatocellular carcinoma (HCC). (2) Therapy for NASH is currently limited to a few pharmacologic agents with unknown long-term efficacy. Guidelines from the American Association for the Study of Liver Diseases recommend pioglitazone as a treatment for NASH, (3) but it is poorly tolerated because of side effects including weight gain and exacerbation of congestive heart failure. (4) Vitamin E is another recommended therapy that led to improvement in liver histology (i.e., steatosis, ballooning, and inflammation) in the PIVENS trial, (5) although metaanalyses and observational studies provide contradictory conclusions regarding the possibility that it may be associated with increased all-cause mortality. (6) (7) (8) Abbreviations: BMI, body mass index; HCC, hepatocellular carcinoma; ICER, incremental cost-effectiveness ratio; ILI, intensive lifestyle intervention; LY, life year; NASH, nonalcoholic steatohepatitis; NNT, number needed to treat; QALY, quality-adjusted life year; RCT, randomized controlled trial.
In recent years, bariatric surgery has emerged as not only an effective weight loss treatment but also a potential therapy for NASH in obese individuals. A 2008 meta-analysis of 15 studies showed an improvement in steatohepatitis and fibrosis in patients with NASH after surgery. (9) One prospective study in obese individuals with NASH demonstrated disease resolution in 85% of individuals at 1 year following surgery, (10) and another showed that the liver-related benefit of surgery was maintained in 69.7% of patients at 5 years. (11) At present, recommendations for bariatric surgery are restricted to patients with body mass index (BMI) 40 or 35 with obesity-related comorbidities. (12) However, specific patient groups with lower BMIs and severe metabolic derangements, such as individuals with diabetes, may also benefit from weight loss surgery. (10, 13) Given the limited medical options for treating NASH, there is growing interest in a potential role for bariatric surgery as therapy for patients with NASH and nonmorbid obesity, although the data in this population are limited. (10) Randomized controlled trials (RCTs) to assess the impact of surgery for this group are unlikely in the near future, due to the expense and the difficulty of recruiting patients who are willing to be randomized. Under these circumstances, where data are limited and RCTs are difficult or unfeasible, modeling can provide a methodologic platform that integrates the best available data to quantitatively explore a clinical decision by simulating a hypothetical RCT between competing strategies.
The aim of our study was to project the long-term clinical outcomes and assess the cost-effectiveness of bariatric surgery or lifestyle intervention for the treatment of NASH in obese and overweight patients. Our goal was to provide insights to clinicians and researchers by generating comparative and cost-effectiveness data.
Materials and Methods

MODEL STRUCTURE
We developed a state-transition model using TreeAge Pro 2015 (TreeAge, Williamstown, MA) to assess three different strategies for treating NASH: no treatment, intensive lifestyle intervention (ILI), and laparoscopic Roux-en-Y gastric bypass surgery.
The simulation began with a hypothetical cohort of 45-year-old men and women with NASH. We modeled patients into various health states, including NASH F0-F3, compensated cirrhosis without HCC, compensated cirrhosis with HCC, decompensated cirrhosis without HCC, decompensated cirrhosis with HCC, and treatment-induced NASH remission. Patients with decompensated cirrhosis and/or HCC were eligible for liver transplantation. Possible causes of death included surgical complications, liver-related mortality, cancer-related mortality, and all-cause mortality. The model cycle length, or time between state transitions, was 1 year. Each year, patients could either remain in the same health state, progress to another, or die ( Fig. 1) . Mortality risk was based on patients' age, sex, BMI, and fibrosis stage. Simulated patients were followed until death.
COMPETING STRATEGIES FOR NASH MANAGEMENT
In the no-treatment strategy, patients did not undergo surgery or other interventions, and their liver disease progressed according to natural history probabilities derived from the literature ( Table 1) .
In the ILI strategy, patients were modeled to undergo a weight loss intervention that involved a combination of diet and exercise. After 1 year, 25% of patients entered a "NASH remission" state. (14) These patients could later relapse and continue progressing toward cirrhosis. In the absence of data on post-ILI NASH relapse, we estimated a relapse rate from a study that examined diabetes relapse in patients who entered diabetes remission after ILI. (15) In the surgery strategy, all NASH patients underwent laparoscopic Roux-en-Y gastric bypass. Patients faced a risk of complications or perioperative mortality (Supporting Table S3 ). After surgery, 69.7% of patients entered "NASH remission" but could later relapse to progressive disease. (11) We derived the probability of disease remission from a 2009 study, which involved collecting liver biopsies at planned intervals over 5 years. (11) Due to a lack of data on the durability of NASH remission after surgery, we approximated NASH disease relapse from studies on diabetes relapse after bariatric surgery. (16, 17) (25) CC to DC 5.8% 4% 16% (21, 24, 28) CC to death 2.09% 2% 4% (21, 24, 28) DC to death 13% 10% 38% (22) CC/DC to HCC 0.69% 0.50% 16.8% (,21-24) HCC to death 42.7% 33.0% 86.0% (30) Treatment efficacy estimates Surgery: probability of NASH remission at year 5 69.7% 30% 100% (11) Surgery: probability of NASH relapse (annual) 6.3% 5.1% 100% (16, 17) ILI: probability of NASH remission at year 1 25% 20% 30% (47) ILI: probability of NASH relapse (annual) 17.7% 3.0% 27.0% (15) Health 
WEIGHT LOSS
We incorporated the impact of weight loss on survival and quality of life for patients in four weight classes: overweight (BMI 25-29.9), mild obesity (BMI 30-34.9), moderate obesity (BMI 35-39.9), and severe obesity (BMI >40). In the no-treatment strategy, patients remained at their initial weight over their lifetime. Weight loss in the ILI strategy was based on results from the Diabetes Prevention Program (18) (Supporting Table S2 ). Postsurgical weight loss was derived from a recent meta-analysis. (19) 
NATURAL HISTORY
We estimated the probability of death according to age, sex, and BMI using data from the US Third National Health and Nutritional Examination Survey. (20) Excess mortality rates were applied for patients with compensated cirrhosis, decompensated cirrhosis, and HCC: 2%, 13%, and 42.7%, respectively (Table  1) . (21) (22) (23) (24) In addition, the modeled natural history of NASH was verified by calibrating disease progression parameters so that 20% of NASH patients ultimately developed cirrhosis in their lifetime. (2, (25) (26) (27) (28) (29) The probability of decompensation for patients with cirrhosis was based on a prospective study of NASH cirrhosis. (19) Patients with compensated or decompensated cirrhosis faced a risk of developing HCC (under 1% each year) (21) (22) (23) (24) 30) (Supporting Table S3 ). In order to reflect the range within the natural history of NASH, we included two different health states in which patients could have HCC: "compensated cirrhosis and HCC" and "decompensated cirrhosis and HCC." We also incorporated probabilities of receiving liver transplantation for patients with decompensated disease or HCC: 2.3% or 4.0%, respectively. During the first year after transplantation, these patients faced elevated risk of mortality.
COSTS AND QUALITY-OF-LIFE ADJUSTMENTS
Costs associated with surgery and complications were derived from the literature (Supporting Table  S3 ). (31) Direct costs associated with different health states were derived using the methodology described by Chhatwal et al. (32) (Supporting Information). All costs from prior years were converted to 2014-year dollars using the Consumer Price Index. (33) Utility estimates were derived from studies on fibrosis or cirrhosis from other causes because there were no quality-of-life studies for NASH cirrhosis that could inform our model; this approach was used in a previous cost-effectiveness analysis studying NASH. (24) Patients who underwent surgery received a quality-oflife decrement, which was applied for 6 weeks. A quality-of-life decrement for major complications was applied for 6 weeks, and quality-of-life decrements were applied for 4 weeks after mild and moderate complications (Supporting Table S3 ). We also adjusted quality of life based on patients' age, sex, and weight class (Table 1; Supporting Table S3 and S4). (34) OUTCOMES Each intervention was tested in 16 patient profiles representing the spectrum of both weight and NASH severity: four weight classes (overweight, mild obesity, moderate obesity, and severe obesity) and four stages of NASH disease (F0-F3).
We determined the gain in life years (LYs), qualityadjusted life years (QALYs), and total costs for patients undergoing ILI or surgery compared with no treatment. We also assessed clinical outcomes, such as the number of patients needed to treat (NNT) to prevent cirrhosis, liver-related death, and liver transplantation.
SOCIETAL COST-EFFECTIVENESS ANALYSIS
From a societal perspective, we assessed the costeffectiveness of surgery and ILI for individuals in different weight classes. Incremental cost-effectiveness ratios (ICERs) were calculated for treatment at earlier stages of NASH versus delaying treatment until a more advanced disease stage. To illustrate, in the strategy "Surgery: All," all patients (i.e., those in fibrosis stages F0-F3) undergo surgery; in contrast, in the "Surgery: F3 Only" strategy, treatment is reserved for patients who initially have F3 fibrosis or develop F3 fibrosis. All future QALYs and costs were discounted at an annual rate of 3%. (35) A willingness-to-pay threshold of $100,000/QALY was used to determine cost-effectiveness. (36, 37) To assess the impact of model input uncertainty on cost-effectiveness results, probabilistic sensitivity analysis was performed for each weight class, where all parameter values were varied simultaneously (Supporting Figs. S1-S4). One-way sensitivity analysis was also performed to assess the impact of uncertainty surrounding individual model parameters on cost-effectiveness outcomes (Supporting Tables S11-S14).
Results
BASE-CASE RESULTS
Surgery led to a gain in QALYs and LYs for all patients, regardless of initial body weight or fibrosis stage (Tables 2 and 3 ). Compared to no treatment, ILI also led to an increase in QALYs and LYs for patients in all weight classes and fibrosis stages (Tables 2 and  3 ). Surgery provided superior outcomes to ILI in terms of both QALYs and LYs.
For bariatric surgery, the NNT values to prevent liver-related death were relatively favorable among F3 patients in all weight classes (Supporting Table S7 ). For overweight F3 patients, the NNT was 8; for severely obese F3 patients, the NNT was 11. The NNTs to prevent new cases of cirrhosis were similarly favorable: 6 for overweight F3 patients and 8 for severely obese F3 patients.
Cost-effectiveness analysis found that surgery is the optimal strategy for all obese patients (with F0-F3). ICERs for performing surgery on all patients with mild, moderate, or severe obesity (versus reserving surgery only for F3 patients) were $48,836/QALY, $24,949/QALY, and $19,222/QALY, respectively (Table 4) . For overweight patients, it was not costeffective to extend surgery to all patients. In the overweight cohort, the cost-effective strategy was to perform surgery on patients once they developed advanced fibrosis (F3), with a corresponding ICER of $30,484/ QALY (versus reserving ILI only for F3 patients). ILI was a less effective option for overweight patients with advanced fibrosis (i.e., it resulted in fewer QALYs), and it yielded an ICER of $25,367/QALY (versus no treatment for any patients). For overweight patients, all other strategies had exceedingly large ICERs or were dominated; i.e., the other strategies cost more and did not result in additional benefit.
SENSITIVITY ANALYSIS
We conducted one-way sensitivity analyses to examine the impact of model input uncertainty on the costeffectiveness outcomes for patients in each weight class, at all stages of fibrosis (Supporting Tables S11- Table S6 . S14). In overweight patients, cost-effectiveness results were sensitive to the following variables: lifetime probability of developing cirrhosis, probability of NASH remission after surgery, and probability of relapse to NASH after surgery. In patients with mild and moderate obesity, cost-effectiveness results were sensitive to the value of weight-related quality of life. In patients with severe obesity, cost-effectiveness results were robust to variations in all model input values. Probabilistic sensitivity analysis assessed the impact of model input uncertainty on the cost-effectiveness results for overweight patients. Our probabilistic sensitivity analysis showed that surgery for only overweight F3 patients is the optimal strategy in 72.4% of simulations, at a willingness-to-pay threshold of $100,000 (Supporting Fig. S1 ). At a willingness-topay threshold of $100,000/QALY, surgery for all patients (i.e., surgery for F0-F3 patients) was the most cost-effective option in 90.9% of simulations for those with mild obesity and in 100% of simulations for those with moderate or severe obesity (Supporting Figs. S1-S4).
Discussion
We found that surgery is cost-effective in all patients with obesity, regardless of fibrosis stage, and in *Results of cost-effectiveness analyses, which were conducted separately for each weight class. ICERs were calculated along an efficiency frontier; in other words, each ICER is calculated relative to the next less expensive nondominated strategy. A strategy that is "dominated" costs more and is not more effective compared to its comparators.
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overweight patients with advanced fibrosis (F3). Our analysis demonstrates the potential value of bariatric surgery and ILI for treating NASH. Although we evaluated the potential benefits and harms of surgery in patients with NASH, a previous study assessed the benefits of bariatric surgery in patients with compensated cirrhosis. (38) We also took the novel approach of simulating surgery to resolve NASH in overweight patients, in addition to obese patients. Although evidence suggests that bariatric procedures are safe and do not lead to excessive weight loss in nonobese patients, there are scant data regarding long-term effects in this group. The lack of data to inform the modeling for this group makes our analysis of overweight patients an exploratory one, yet our results highlight the promise that surgery may hold for this population and underscore the need for additional research in this area.
At present, coverage for surgery is restricted to patients with BMI 40 or 35 with obesity-related comorbidities. (12) Our analysis demonstrated an increase in life expectancy and quality-adjusted survival after surgery in patients in all classes of obesity-even those with BMI between 30 and 35. These results affirm previous studies showing a benefit of surgery for patients with mild obesity. (31, 39) Thus, our analysis lends support to recommendations to extend coverage for bariatric procedures to patients with BMI between 30 and 35 with obesity-related comorbidities, such as NASH. (40, 41) Our analysis also establishes a framework to assess the comparative effectiveness of surgery versus lifestyle intervention for patients with NASH. Compared with lifestyle intervention, surgery led to more QALYs for all obese patients and overweight patients, regardless of fibrosis stage (Table 2) . Surgery also led to superior outcomes in life expectancy for all patient cohorts assessed (Table 3 ). While our results affirm the superior effectiveness of surgery versus nonsurgical intervention, (42, 43) the difference in QALYs between surgery and ILI is negligible in overweight patients without severe fibrosis. This result suggests that lifestyle intervention plays an important role in weight management for overweight patients without severe fibrosis, particularly in highly motivated patients who are willing and able to adhere to a long-term regimen. In addition, the rate of disease progression and benefits of bariatric surgery may differ according to clinical characteristics other than weight class and fibrosis stage, including Brunt score, race, age, and diabetes status, which suggests that additional methods for risk stratification may enhance optimal patient selection for bariatric surgery in the future. (10, 44) As with any modeling study, ours has limitations. First, we made the assumption that bariatric surgery has an effect on NASH remission. Although compelling evidence supports this effect, the lack of RCT data means that we cannot definitively attribute postsurgical liver-related benefit to bariatric procedures. We also made the simplifying and biologically plausible assumption that the NASH remission rates after surgery were constant across all weight classes, although our analysis was based on data from patients with BMI >35. In addition, there was a lack of data on durability of NASH remission following surgery, so we used diabetes relapse data from the Swedish Obese Subjects study as a stand-in for the probability of NASH relapse (16) ; similarly, the probability of NASH relapse after ILI was based on a study of lifestyle intervention in individuals with diabetes. (15) While not ideal, these assumptions are consistent with our understanding of diabetes and NASH as manifestations of metabolic syndrome, with underlying mechanisms that are closely connected. (45) We also estimated the costs of treating NASH using data from patients with hepatitis C because of a lack of cost data for NASH-specific health states. (32) Moreover, we chose to limit our analysis of bariatric procedures to laparoscopic Roux-en-Y gastric bypassthe gold-standard bariatric procedure in the United States. Our selection of laparoscopic Roux-en-Y gastric bypass influenced postsurgical weight loss, complications, and costs incurred for patients in our analysis. While it would be interesting to extend this analysis to sleeve gastrectomy, the other prominent bariatric surgery in the United States, there are scant data demonstrating the effects of this procedure on NASH patients. (10) Studies on postsurgical NASH remission have examined a variety of bariatric procedures (gastric band, biliointestinal bypass, gastric bypass, and sleeve gastrectomy), but there are currently insufficient data to compare the efficacy of laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy in terms of their benefit for individuals with NASH. As more data continue to accrue regarding other bariatric procedures, we can perform additional analyses.
Despite these caveats, our analysis has several merits. Our study is a most comprehensive analysis that assesses the effectiveness and cost-effectiveness of bariatric surgery in individuals with NASH. It highlights a potential treatment for NASH, a disease that currently has limited therapeutic options. Many patients who undergo bariatric surgery for the purposes of weight loss or management of type 2 diabetes also suffer from NASH; for these individuals, surgery may confer additional meaningful benefits, as our study demonstrates. Our analysis also highlights a potential public health role of bariatric surgery as it has the potential to curb the rise in liver transplantations performed for NASH cirrhosis. NASH is predicted to be the leading indication for transplants by 2025, so this will become a pressing priority in the years ahead. (46) According to our analysis, the NNT to prevent a liver transplant among severely obese F3 patients is 119 (Supporting Table S7 ). While this NNT is high, it points toward a potential role for bariatric surgery in lessening the demand for liver transplantation due to an indication of NASH cirrhosis.
In summary, our analysis finds that bariatric surgery and lifestyle intervention are effective treatments for patients with NASH in all obesity classes. For overweight patients, our results suggest that surgery is more effective than lifestyle intervention (i.e., it leads to a larger increase in QALYs) in all individuals, regardless of fibrosis stage. Our analysis also suggests that bariatric surgery is a cost-effective therapy for patients in all classes of obesity and may even be costeffective for treating overweight individuals with advanced fibrosis (F3). Given the growing burden of NASH, our promising results underscore the need to plan a clinical trial to assess the comparative benefits of bariatric surgery and lifestyle intervention for patients with NASH, including those who are not obese.
